BellaSeno Receives Financial Support Through Queensland’s Industry Partnership Program
05 juin 2024 04h00 HE
|
AKAMPION
Funding to support establishment of the world´s first fully automated production facility for resorbable medical scaffolds based in AustraliaAI-driven, no-touch manufacturing to ensure highest...
selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis
28 mai 2024 04h00 HE
|
AKAMPION
- New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si-544 in the treatment of T cell autoimmunity ...
Captain T Cell Secures Seed Financing Round Totaling € 8.5 Million
22 mai 2024 04h00 HE
|
AKAMPION
i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH and HIL-INVENT Ges.m.b.H. participated in the seed roundFunds will be used to accelerate a new generation of T cell therapies against solid tumors...
Atopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business Update
07 mai 2024 04h09 HE
|
AKAMPION
Geneva (Switzerland), May 7, 2024 – Atopia Therapeutics, a leader in the development of breakthrough asthma and allergy therapies, today announced the appointment of Dr. Grégoire Chevalier as Chief...
selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis
29 avr. 2024 04h00 HE
|
AKAMPION
si-544 was well tolerated with no serious adverse effects, dose limiting toxicities, or safety signals observed75% of patients receiving si-544 experienced objective clinical improvement, of which 44%...
Mit biomedizinischer Forschung schneller zum Patienten: ForTra gGmbH gibt positive Förder-Bilanz bekannt
23 avr. 2024 04h00 HE
|
AKAMPION
Lücke zwischen Grundlagenforschung und klinischer Anwendung schließenMehr als 50 Prozent aller geförderten Projekte erhalten Anschlussfinanzierung Bad Homburg v.d. Höhe, 23.04.2024 – Die...
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track Record
23 avr. 2024 04h00 HE
|
AKAMPION
Closing the gap between basic research and clinical applicationMore than 50 percent of all funded projects received follow-up funding Bad Homburg v.d. Höhe, Germany, April 23, 2024 - ForTra gGmbH...
BellaSeno Appoints Dr. Thomas Lingner as Chief Technology Officer and Inga Freyert as VP Quality and Regulatory Affairs
03 avr. 2024 04h00 HE
|
AKAMPION
Further expansion of management expertise to accelerate BellaSeno´s market entry Leipzig, Germany, April 3, 2024 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable...
MetrioPharm stellt wissenschaftlichen Beirat aus erfahrenen Immunologie- und Pädiatrie-Experten vor
13 mars 2024 06h00 HE
|
AKAMPION
Die neuen Beiräte werden ihr Fachwissen in den Bereichen Immunologie, Pathologie, Entzündungsprozesse und in MetrioPharms Hauptindikation Duchenne-Muskeldystrophie einbringenDie Beiräte haben bereits...
MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts
13 mars 2024 06h00 HE
|
AKAMPION
The new advisors will supply expertise in immunology, pathology, inflammatory processes and in MetrioPharm's lead indication Duchenne muscular dystrophy Advisors have previously collaborated with...